What triggered Nano Dimension shares' latest price pullback

Traders Union
All News
Financial News
Nano Dimension slips 8.05% today

Highlights

Nano Dimension will merge with Infinite Epigenetics in a stock-for-stock deal, creating an AI-focused diagnostics company valued at $890 million.
The combined entity targets the $94 billion US diagnostics market, leveraging a proprietary biological data platform and strong IP portfolio.
Shares trade under bearish pressure with the price expected to consolidate between $1.32 and $1.45, amid sustained negative momentum and oversold technical signals.

Merger expansion meets ongoing selling despite diagnostics sector push

Nano Dimension announced a stock-for-stock merger to form an AI-powered diagnostics company focused on early detection of chronic diseases. The combined entity will utilize a proprietary biological data platform and a portfolio of intellectual property, with the deal valuing the merger counterpart Infinite Epigenetics at $890 million and aiming to target a $94 billion US diagnostics market. This transaction expands Nano Dimension's presence in the diagnostics sector, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, highlights enduring bearish pressure in Nano Dimension Ltd. He notes that the stock sits well below all major moving averages. News of the high-profile merger has not been enough to reverse prevailing negative sentiment. Technical indicators reinforce a weak momentum profile, with oscillators showing clear oversold conditions. "I remain skeptical about a swift turnaround as the technical and sentiment picture offers little to support aggressive buying at these levels," Kharitonov concludes.

Viktoras Karapetjanc, expert at Traders Union, sees long-term opportunity in Nano Dimension’s strategic merger move. He points to the company's expansion into the vast US diagnostics market as a forward-looking catalyst. Despite current downside, Karapetjanc believes the combined platform and intellectual property can drive future growth. "The bullish structure remains intact for patient investors as Nano Dimension pivots toward high-value diagnostics," Karapetjanc says.

Oversold signals and negative momentum define intraday direction

Nano Dimension is trading below its MA-20 ($1.61), MA-50 ($1.69), and MA-200 ($1.70), reflecting persistent short-, medium-, and long-term bearish pressure. The nearest dynamic resistance is defined by the Ichimoku Kijun line at $1.67, with little sign of immediate support from moving averages. Current momentum remains negative as both the Moving Average Convergence Divergence (MACD) and the Average Directional Index (ADX) indicate a continuation of the selloff without a strong trend. The Relative Strength Index (RSI) at 38.71, Stochastic RSI at 3.91, and Commodity Channel Index (CCI) at -92.06 all signal an oversold environment on the daily timeframe. Bull/Bear Power (BBP) at -0.06 suggests sellers clearly dominate intraday action, further reinforced by an oversold signal from oscillators. Awesome Oscillator (AO) likewise points lower, supporting downside pressure. After opening with an upside gap of about $0.03, the stock has dropped substantially, now trading near the low of the day at $1.37, down 8.05% from the most recent close as intraday volatility stands at 3.40%. There is pronounced pressure after the open, and intraday direction aligns solidly with the negative momentum backdrop.

Earlier, analysts noted that Nano Dimension was exhibiting persistent bearish momentum and sustained downside risk. The latest merger announcement and continued technical weakness reinforce this cautious outlook, with attention now on the $1.32 support level as a critical threshold for potential further declines in the coming days.

Source of Data: NNDM Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.